The technology is a series of modafinil analogues that bind with moderate to high affinity to the dopamine (DA) transporter (DAT). Some compounds also have affinity for the serotonin (5-HT) transporter (SERT) and/or sigma-1 receptor. The compounds retain the desired dopamine transporter affinity with greater metabolic stability over previously described unsubstituted piperazine ring analogues. Importantly, these compounds have no predicted addictive liability. Also disclosed are methods for treating substance use disorders as well as other neuropsychiatric disorders such as ADHD, depression, narcolepsy, and cognitive impairment. Researchers at the National Institute on Drug Abuse (NIDA) seek licensing and/or co-development research collaborations for further development and commercialization of the compounds.
Recombinant human tissue inhibitors of metalloproteinases (rhTIMP-2) have been shown to suppress tumor growth and tumor-associated angiogenesis. NCI Radiation Oncology Branch (ROB) researchers have developed a unique HEK-293F cell line which stably expresses rhTIMP-2, increasing the production of TIMP-2 to quantities sufficient to be used for testing and development as a therapeutic for various cancers, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases.
Hibernation in mammals is a seasonal state of metabolic suppression and dormancy characterized by a decrease in body temperature to survive extreme environmental stresses. A new Induced Pluripotent Stem Cell (iPSC) line has been established from the neural precursor cells of wild type thirteen-lined ground squirrel (Spermophilus tridecemlineatus), a small mammalian hibernator with unique metabolic adaptations for coping with cold and restricted food supply. This ground squirrel iPSC line can be differentiated into many different cell types for hibernation studies, disease modeling, and drug screening for neuronal injuries or other diseases.
Researchers at the National Cancer Institute (NCI) developed a genetic assay for detecting transcription errors in RNA synthesis. This new assay extends the familiar concept of an Ames test which monitors DNA damage and synthesis errors to the previously inaccessible issue of RNA synthesis fidelity. The FDA requires genetic DNA focused tests for all drug approval as it assesses the in vivo mutagenic and carcinogenic potential of a drug. The new assay will open an approach to monitoring the impact of treatments on the accuracy of RNA synthesis. Errors in transcription have been hypothesized to be a component of aging and age-related diseases. The National Cancer Institute (NCI) seeks licensing partners for the genetic assay.
The Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD) seeks research and co-development partners or licensees for an invention that discloses the diagnosis of pathologies in tissue related to changes in cell size, cellularity, cell infiltration, and other abnormalities detected by bulk water diffusion changes.
Researchers at the NICHD seek licensing and/or co-development research collaborations for an MRI method that is based on the measurement and acquisition of multiple pulsed field gradient (m-PFG) rather than the previously used single pulsed field gradient (s-PFG) MRI sequences.
Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (“NICHD”), seek CRADA partner or collaboration for development of agents to treat multiple sclerosis or other conditions associated with myelin remodeling by administering an agent that inhibits cleavage of Neurofascin 155 or Caspr1. The agent could be a thrombin inhibitor, an agent that inhibits thrombin expression, an anti-thrombin antibody that specifically inhibits thrombin mediated cleavage of Neurofascin 155, a mutated version or fragment of Neurofascin 155 or Caspr1, or antibodies to Neurofascin 155 or Caspr1.
Researchers at the NICHD developed a method for non-invasively determining the distribution of pore lengths and radii within a matrix thereby characterizing cognitive defects observed in patients with Traumatic Brain Injury (TBI). The NICHD seeks licensing and/or co-development research collaborations to bring this invention to the public.
Researchers at the National Cancer Institute (NCI) RNA Biology Laboratory have developed nanoparticles that can deliver an agent (i.e., therapeutic or imaging) and release the agent upon targeted photoactivation allowing for controlled temporal and localized release of the agent.
The technology is directed to the use of single-stranded RNA overhangs or toeholds of varying lengths (< 12 nucleotides) contained in nucleic acid-based nanoparticles which trigger the association of these nanoparticles and activates multiple functionalities such as gene silencing and/or cell-specific targeting. The use of RNA toeholds is superior to that of DNA toeholds in that it allows for smaller nanoparticles (fewer nucleotides for the toeholds) resulting in greater chemical stability, less immunogenic and higher yield of production. The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for use of RNA overhangs or toeholds in nucleic acid nanoparticles.
The Section on Translational Neuroscience of NICHD seeks parties interested in licensing and/or collaborative research to co-develop this therapeutic management of Menkes Disease and related copper transport disorders.
The National Cancer Institute seeks parties interested in collaborative research to co-develop or license methods of treating disorders related to polyomavirus, as well as vaccines for patients undergoing immunosuppressive treatment such as multiple sclerosis, rheumatoid arthritis, B cell cancers, and Crohn’s disease.